Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Phase 2
64
about 5.7 years
0.00273790700698851–0.5
11 sites in AL, CA, CO +7
Why this study is shown
What this study is about
Researchers are testing sirolimus to prevent or delay seizures in children with Tuberous Sclerosis Complex (TSC). The trial will last for about two years. Participants will be randomly assigned to receive either a placebo or sirolimus.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Sirolimus
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
sirolimus
injection, intravenous
Primary: Safety -- adverse events
Secondary: MRI Biomarkers, Quality of Life Outcomes
Neurology